Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181756 | 1.00 | SMO (0.49) | SMOKCNH2MCHR1HRH4ACKR3 | |
| SCHEMBL24033331 | 0.89 | OPRK1 (0.50) | SMO | |
| SCHEMBL29134381 | 0.88 | KCNH2 (0.52) | KCNH2MCHR1HRH4ACKR3 | |
| SCHEMBL29134379 | 0.88 | KCNH2 (0.52) | KCNH2MCHR1HRH4ACKR3 | |
| Lithium SCHEMBL30665070 | 0.87 | KCNH2 (0.51) | KCNH2MCHR1HRH4ACKR3 | |
| SCHEMBL29134617 | 0.87 | KCNH2 (0.51) | KCNH2MCHR1HRH4ACKR3 | |
| SCHEMBL29134615 | 0.87 | KCNH2 (0.51) | KCNH2MCHR1HRH4ACKR3 | |
| SCHEMBL30390753 | 0.86 | HRH3 (0.49) | KCNH2MCHR1HRH4ACKR3 | |
| Lithium Ion SCHEMBL30196838 | 0.85 | KCNH2 (0.47) | KCNH2MCHR1HRH4ACKR3 | |
| SCHEMBL24033384 | 0.84 | SMO (0.48) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | SMO 3615/4885KCNH2 3605/4885MCHR1 593/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | SMO 3615/4885KCNH2 3605/4885MCHR1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.